Addressing the Clinical Feasibility of Adopting Circulating miRNA for Breast Cancer Detection, Monitoring and Management with Artificial Intelligence and Machine Learning Platforms

Detecting breast cancer (BC) at the initial stages of progression has always been regarded as a lifesaving intervention. With modern technology, extensive studies have unraveled the complexity of BC, but the current standard practice of early breast cancer screening and clinical management of cancer...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2022-12, Vol.23 (23), p.15382
Main Authors: Ling, Lloyd, Aldoghachi, Ahmed Faris, Chong, Zhi Xiong, Ho, Wan Yong, Yeap, Swee Keong, Chin, Ren Jie, Soo, Eugene Zhen Xiang, Khor, Jen Feng, Yong, Yoke Leng, Ling, Joan Lucille, Yan, Naing Soe, Ong, Alan Han Kiat
Format: Article
Language:English
Subjects:
Artificial Intelligence
Biomarkers
Biomarkers, Tumor - genetics
Biopsy
Blood circulation
Breast cancer
Breast Neoplasms - diagnosis
Breast Neoplasms - genetics
Breast Neoplasms - pathology
Cancer screening
Cancer therapies
Chemotherapy
Circulating MicroRNA
circulating miRNA
Female
Humans
Invasiveness
Learning algorithms
liquid biopsy
Machine Learning
Mammography
Medical prognosis
Metastasis
MicroRNAs
MicroRNAs - genetics
miRNA
Mortality
Plasma
Review
Survival analysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Detecting breast cancer (BC) at the initial stages of progression has always been regarded as a lifesaving intervention. With modern technology, extensive studies have unraveled the complexity of BC, but the current standard practice of early breast cancer screening and clinical management of cancer progression is still heavily dependent on tissue biopsies, which are invasive and limited in capturing definitive cancer signatures for more comprehensive applications to improve outcomes in BC care and treatments. In recent years, reviews and studies have shown that liquid biopsies in the form of blood, containing free circulating and exosomal microRNAs (miRNAs), have become increasingly evident as a potential minimally invasive alternative to tissue biopsy or as a complement to biomarkers in assessing and classifying BC. As such, in this review, the potential of miRNAs as the key BC signatures in liquid biopsy are addressed, including the role of artificial intelligence (AI) and machine learning platforms (ML), in capitalizing on the big data of miRNA for a more comprehensive assessment of the cancer, leading to practical clinical utility in BC management.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms232315382